Medmen: Canaccord Raises Price Target, Rating After Q4 Performance
On September 23, Medmen Enterprises (CSE: MMEN) reported their fiscal fourth-quarter financial results. The company reported revenue of $42 million,
Read more
MedMen Enterprises
Medmen Posts Q4 Loss Of $46.2 Million
Medmen Enterprises (CSE: MMEN) last night reminded investors why Canaccord Genuity had a long standing $0.00 price target on the
Read more
Tilray Sees Gotham Green Look To Sell Recently Acquired Shares
It appears that Gotham Green Partners has approximately zero interest in being a shareholder of Tilray Inc (TSX: TLRY) (NASDAQ:
Read more
Tilray: Analysts Leave Targets Unchanged After MedMen Investment
On August 17, Tilray (NASDAQ: TLRY) made the announcement that they formed a new limited partnership with other strategic investors,
Read more
Tilray Makes Move Into US Cannabis Market Via Medmen Convertible Notes
It appears that the rumours surrounding Tilray’s (NASDAQ: TLRY) focus on the US cannabis market were true. The firm this
Read more
Canaccord Reiterates $0.00 Price Target On Medmen
Medmen Enterprises’ (CSE: MMEN) reported their fiscal third quarter 2021 financial results on May 11th after market close. The company
Read more
MSO Hiring Through A Year of COVID-19 – Trulieve Leads The Way
The outbreak of COVID-19 threw a wrench into the plans of many companies who were forced to shelve their growth
Read more
Medmen: Canaccord Reiterates $0 Price Target, Sell Rating
On December 7th, Medmen Enterprises’ (CSE: MMEN) reported first-quarter fiscal 2021 financial results. Medmen reported revenues of $35.6 million, up
Read more
Canaccord Drops Medmen Price Target To $0.00, Reiterates Sell Rating
After Medmen Enterprises’ (CSE: MMEN) fourth-quarter results dropped after hours on October 15th, Canaccord downgraded Medmen’s 12-month price target to
Read more
MedMen Sees Founders Sell Shares Continuously Through July
Evidently, now is a bad time to hold equity in Medmen Enterprises (CSE: MMEN) – that is, if you’re one
Read more